Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2018 01:58 ET | Source: MannKind

MannKind Announces $28.0 Million Registered Direct Offering

WESTLAKE VILLAGE, Calif., April 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) today announced the pricing of a registered direct offering of 14,000,000 shares of common stock and...
March 19, 2018 08:00 ET | Source: MannKind

MannKind Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference

WESTLAKE VILLAGE, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with...
March 14, 2018 08:00 ET | Source: MannKind

MannKind Corporation to Present at Oppenheimer 28th Annual Healthcare Conference

WESTLAKE VILLAGE, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with...
March 13, 2018 08:00 ET | Source: MannKind

MannKind Announces STAT Study Results Accepted for Presentation at American Diabetes Association’s 78th Scientific Sessions

WESTLAKE VILLAGE, Calif., March 13, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) focused on the development and commercialization of inhaled therapeutic products for patients with...
March 12, 2018 08:08 ET | Source: MannKind

MannKind Restructures $79.7 Million Debt Obligation to the Mann Group and Reduces Principal Owed to Deerfield by $6.3 Million

WESTLAKE VILLAGE, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced the restructuring of certain of its outstanding debt obligations, reducing...
March 01, 2018 16:01 ET | Source: MannKind

MannKind Opens Enrollment of Phase 1 Trial of Treprostinil Technosphere for Pulmonary Arterial Hypertension

WESTLAKE VILLAGE, Calif., March 01, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with...
February 27, 2018 16:01 ET | Source: MannKind

MannKind Corporation Reports 2017 Fourth Quarter and Full Year Financial Results

Q4 and 2H 2017 Afrezza net revenue were $4.5 million (+238%) and $6.4 million (+240%) vs. 2016, respectivelyQ4 and 2H 2017 net cash used in operating activities were $30.0 million and $53.3 million,...
February 23, 2018 08:00 ET | Source: MannKind

MannKind Corporation to Hold 2017 Fourth Quarter and Full Year Financial Results Conference Call on February 27, 2018

WESTLAKE VILLAGE, Calif., Feb. 23, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD) will release its 2017 fourth quarter and full year financial results on Tuesday, February 27, 2018 and...
February 06, 2018 08:00 ET | Source: MannKind

David Kendall Joins MannKind as Chief Medical Officer

WESTLAKE VILLAGE, Calif., Feb. 06, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) today announced that David M. Kendall, MD, will join the company as Chief Medical Officer and assume...
January 16, 2018 09:00 ET | Source: MannKind

MannKind Corporation to Present at NobleCon14 - Noble Capital Markets’ Fourteenth Annual Investor Conference

WESTLAKE VILLAGE, Calif., Jan. 16, 2018 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq:MNKD), focused on the development and commercialization of inhaled therapeutic products for patients with...